Comparison of desmopressin and enuresis alarm for nocturnal enuresis.

Wille S

Archives of disease in childhood1 Jan 1986Cited by 80 (Europe PMC)

PMID3513716PMCIDPMC1777552DOI10.1136/adc.61.1.30PepBankPUB-03513716

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with primary nocturnal enuresis, improvement was 70% with desmopressin versus 86% with alarm, without a significant difference.
In plain wordsIn children with nocturnal enuresis, improvement rates did not differ significantly between desmopressin and alarm.
Peptide
Desmopressin
Outcome
No significant changeImprovement rate
Study
n = 46
Comparator
Enuresis alarm
Outcome group
Enuresis · Kidney and urinary
Studied dose
20 micrograms nightly · intranasal · three monthsAs given in this study (human).
Measurements
Improvement rate
70%
intranasal desmopressin group
Improvement rate
86%
enuresis alarm group
Source sentences
Summary
The improvement rate was 70% in the group given desmopressin and 86% in the group treated with alarm; the difference was not significant.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty children with primary nocturnal enuresis were randomised for a study comparing desmopressin (DDAVP) and enuresis alarm.
Summary · context
Forty six completed the trial, 24 of whom were treated with 20 micrograms intranasal desmopressin nightly and 22 with enuresis alarm for three months.
Report a problemFND-0351371601
02HumanRandomized controlled trialEfficacy outcome
In children with nocturnal enuresis, desmopressin produced significantly greater dryness than alarm during the first week.
In plain wordsIn children with nocturnal enuresis, desmopressin produced greater dryness than alarm during the first week.
Peptide
Desmopressin
Outcome
IncreaseFirst-week dryness
Study
n = 46
Comparator
Enuresis alarm
Outcome group
Enuresis · Kidney and urinary
Studied dose
20 micrograms nightly · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
During the first week of treatment the group given desmopressin was significantly dryer, and at the end of the study 10 of these patients relapsed compared with one patient in the group given the alarm.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty children with primary nocturnal enuresis were randomised for a study comparing desmopressin (DDAVP) and enuresis alarm.
Summary · context
Forty six completed the trial, 24 of whom were treated with 20 micrograms intranasal desmopressin nightly and 22 with enuresis alarm for three months.
Report a problemFND-0351371602
03HumanRandomized controlled trialEfficacy outcome
In children with nocturnal enuresis, 10 desmopressin patients relapsed versus one alarm patient at study end.
In plain wordsIn children with nocturnal enuresis, relapse occurred more often after desmopressin than alarm.
Peptide
Desmopressin
Outcome
IncreaseRelapse
Study
n: not reported in source
Comparator
Enuresis alarm
Outcome group
Enuresis · Kidney and urinary
Studied dose
20 micrograms nightly · intranasal · three monthsAs given in this study (human).
Measurements
Patients who relapsed
10 patients
desmopressin group, end of study
Patients who relapsed
1 patients
enuresis alarm group, end of study
Source sentences
Summary
During the first week of treatment the group given desmopressin was significantly dryer, and at the end of the study 10 of these patients relapsed compared with one patient in the group given the alarm.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty children with primary nocturnal enuresis were randomised for a study comparing desmopressin (DDAVP) and enuresis alarm.
Summary · context
Forty six completed the trial, 24 of whom were treated with 20 micrograms intranasal desmopressin nightly and 22 with enuresis alarm for three months.
Report a problemFND-0351371603
04HumanNon-randomized trialSafety outcome
In children with nocturnal enuresis, no serious side effects were observed during the trial of desmopressin and alarm.
In plain wordsIn children with nocturnal enuresis, no serious side effects occurred during the desmopressin and alarm trial.
Peptide
Desmopressin
Outcome
Not applicableSerious side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
20 micrograms nightly · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
No serious side effects were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty children with primary nocturnal enuresis were randomised for a study comparing desmopressin (DDAVP) and enuresis alarm.
Summary · context
Forty six completed the trial, 24 of whom were treated with 20 micrograms intranasal desmopressin nightly and 22 with enuresis alarm for three months.
Report a problemFND-0351371604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.